Literature DB >> 20457117

The amplification loop of the complement pathways.

Peter J Lachmann1.   

Abstract

The C3 amplification loop lies at the core of all the complement pathways, rather than the alternative pathway alone. It is, in evolutionary terms, the oldest part of the complement system and its antecedents can be seen in insects and in echinoderms. The amplification loop is the balance between two competing cycles both acting on C3b: the C3 feedback cycle which enhances amplification and the C3 breakdown cycle which downregulates it. It is solely the balance between their rates of reaction on which amplification depends. The C3 breakdown cycle generates iC3b as its primary reaction product. iC3b, through its reaction with the leukocyte integrins (and complement receptors) CR3 (CD11b/CD18) and CR4 (CD11c/CD18), is the most important mechanism by which complement mediates inflammation. A variety of genetic polymorphisms in components of the amplification loop have been shown to predispose to two kidney diseases-dense deposit disease and atypical haemolytic uraemic syndrome-and to age-related macular degeneration. All predisposing alleles enhance amplification, whereas protective alleles downregulate amplification. This leads to the conclusion that there is a "hyperinflammatory complement phenotype" determined by these polymorphisms. This hyperinflammatory phenotype protects against bacterial infections in early life but in later life is associated with immunopathology. Besides the diseases already mentioned, there is evidence that this hyperinflammatory complement phenotype may predispose to accelerated atherosclerosis and also shows an association with Alzheimer's disease. Downregulation of the amplification loop therefore constitutes an important therapeutic target. 2009 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20457117     DOI: 10.1016/S0065-2776(08)04004-2

Source DB:  PubMed          Journal:  Adv Immunol        ISSN: 0065-2776            Impact factor:   3.543


  82 in total

1.  Use of time-resolved FRET to validate crystal structure of complement regulatory complex between C3b and factor H (N terminus).

Authors:  Isabell C Pechtl; Robert K Neely; David T F Dryden; Anita C Jones; Paul N Barlow
Journal:  Protein Sci       Date:  2011-12       Impact factor: 6.725

Review 2.  C3 glomerulopathy: a new classification.

Authors:  Fadi Fakhouri; Véronique Frémeaux-Bacchi; Laure-Hélène Noël; H Terence Cook; Matthew C Pickering
Journal:  Nat Rev Nephrol       Date:  2010-07-06       Impact factor: 28.314

3.  Properdin homeostasis requires turnover of the alternative complement pathway.

Authors:  Xiaobo Wu; Thomas Q Xu; John P Atkinson
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-25       Impact factor: 11.205

4.  Blocking Properdin Prevents Complement-Mediated Hemolytic Uremic Syndrome and Systemic Thrombophilia.

Authors:  Yoshiyasu Ueda; Takashi Miwa; Damodar Gullipalli; Sayaka Sato; Daisuke Ito; Hangsoo Kim; Matthew Palmer; Wen-Chao Song
Journal:  J Am Soc Nephrol       Date:  2018-06-01       Impact factor: 10.121

Review 5.  Review: Complement and its regulatory proteins in kidney diseases.

Authors:  Allison M Lesher; Wen-Chao Song
Journal:  Nephrology (Carlton)       Date:  2010-10       Impact factor: 2.506

Review 6.  Complementopathies.

Authors:  Andrea C Baines; Robert A Brodsky
Journal:  Blood Rev       Date:  2017-02-06       Impact factor: 8.250

Review 7.  The Evolving Landscape for Complement Therapeutics in Rheumatic and Autoimmune Diseases.

Authors:  Joshua M Thurman; Ashley Frazer-Abel; V Michael Holers
Journal:  Arthritis Rheumatol       Date:  2017-10-17       Impact factor: 10.995

Review 8.  Targeting mechanisms at sites of complement activation for imaging and therapy.

Authors:  V Michael Holers
Journal:  Immunobiology       Date:  2015-04-30       Impact factor: 3.144

9.  Properdin binding to complement activating surfaces depends on initial C3b deposition.

Authors:  Morten Harboe; Christina Johnson; Stig Nymo; Karin Ekholt; Camilla Schjalm; Julie K Lindstad; Anne Pharo; Bernt Christian Hellerud; Kristina Nilsson Ekdahl; Tom Eirik Mollnes; Per H Nilsson
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-09       Impact factor: 11.205

10.  Inhibition of complement C5 protects against organ failure and reduces mortality in a baboon model of Escherichia coli sepsis.

Authors:  Ravi Shankar Keshari; Robert Silasi; Narcis Ioan Popescu; Maulin Mukeshchandra Patel; Hala Chaaban; Cristina Lupu; K Mark Coggeshall; Tom Eirik Mollnes; Steven J DeMarco; Florea Lupu
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-18       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.